Search clinical trials for: Indacaterol (QAB149)

Total 159 results

Novartis Pharmaceuticals

Completed

Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD (INHALE)

Chronic Obstructive Pulmonary Disease

United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma

Asthma

South Africa, Belgium, Croatia, Turkey, Hungary, Colombia, Slovakia, Philippines, Russian Federation, Guatemala, Germany
Novartis

Completed

Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function

Hepatic Insufficiency

United States
Novartis

Completed

Effect of Indacaterol on Inspiratory Capacity and Lung Function in Patients With COPD Versus Placebo and Formoterol

COPD

United Kingdom
Novartis

Completed

Evaluation of Pharmacokinetic Interaction of Indacaterol With Ketoconazole in Healthy Adult Subjects

Healthy

India
Novartis Pharmaceuticals

Completed

Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Belgium, Netherlands, Canada, United States
Novartis

Completed

Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

France, Germany, Belgium, Spain, Turkey, Italy, Canada, Australia
University Medical Center Groningen
Novartis

Completed

Anti-inflammatory Effects Glycopyrronium

Asthma | Allergic Asthma

Netherlands
Novartis Pharmaceuticals

Completed

Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
Novartis Pharmaceuticals

Completed

A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (SHINE)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Russian Federation, Taiwan, Canada, Germany, Philippines, South Africa, Spain, United Kingdom, Turkey, Hungary, Guatemala, Australia, Bulgaria, France, Poland, Switzerland, Slovakia, Japan
Novartis Pharmaceuticals

Completed

Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma (QAB149)

Asthma

United States
Novartis

Completed

Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
Novartis
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Indacaterol Maleate/Mometasone Furoate Delivered Via the Twisthaler® Device After 14 Days Treatment in Patients With Mild to Moderate Asthma

Asthma

France
Yuan-Ming Luo

Completed

Comparison of Tai Chi and Pulmonary Rehabilitation on the Effect of Indacaterol in Treatment naïve COPD Participants

Chronic Obstructive Pulmonary Disease

China
Novartis Pharmaceuticals

Completed

To Determine the Relationship Between Baseline Reversibility and the Efficacy of Indacaterol (REVERBREZ)

Chronic Obstructive Pulmonary Disease (COPD)

France
Novartis

Completed

Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Spain, France
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

China, Australia, India
Morten Hostrup, PhD

Recruiting

U-LABA/ICS Effects on Exercise Performance, Indacaterol

Exercise Performance

Denmark
Novartis Pharmaceuticals

Completed

A Study to Evaluate the Effects of Indacaterol Maleate as a New Formulation in the Concept 1 Device

Asthma

Germany, United Kingdom
Novartis Pharmaceuticals

Withdrawn

A Study to Evaluate the Effects of Indacaterol Maleate (QAB149) as a New Formulation in the EPIC Test Fixture

Asthma
Novartis Pharmaceuticals

Completed

Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma

Mild Asthma

Germany, India, Korea, Republic of, Poland, South Africa, Estonia, Italy, Russian Federation, Thailand, Latvia, Lithuania, Colombia, Hungary, Peru, Philippines, Slovakia, Bulgaria, Vietnam, Japan, Malaysia, Chile, Sweden
Novartis Pharmaceuticals

Completed

Indacaterol EfectIveness In COPD Patients With Tuberculosis History (INFINITY)

Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis

Korea, Republic of
Novartis Pharmaceuticals

Completed

A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Sweden, Denmark, Norway
Novartis

Completed

Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks

Chronic Obstructive Pulmonary Disease

United States
Novartis Pharmaceuticals

Completed

Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BEACON)

Chronic Obstructive Pulmonary Disease

Netherlands, Austria, Denmark, Norway, Sweden
Novartis Pharmaceuticals

Completed

A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

United States, Romania, Hungary, Bulgaria, Spain, Finland, Puerto Rico
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol

Persistent Asthma

United States, Netherlands, United Kingdom, France, Germany, Jordan
Novartis Pharmaceuticals

Completed

A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

Chronic Obstructive Pulmonary Disease (COPD)

United States, Poland, Romania, Canada, Philippines, Spain, Ukraine, Vietnam
Novartis Pharmaceuticals

Completed

Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Salts in Patients With Asthma

Asthma

Italy, Germany, France
Novartis Pharmaceuticals

Completed

A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

United States, Colombia, Egypt, Hungary, France, Guatemala, Panama, Slovakia, Slovenia
Novartis

Completed

12-week Efficacy of Indacaterol

Chronic Obstructive Pulmonary Disease

United States
Novartis

Completed

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, New Zealand, Belgium
Novartis

Completed

Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Japan
Novartis Pharmaceuticals

Completed

Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Taiwan, Korea, Republic of, Japan, India, Hong Kong, Singapore
Novartis Pharmaceuticals

Completed

Efficacy and Safety Study of QVA149 in COPD Patients

Chronic Obstructive Pulmonary Disease

United States
Novartis

Completed

An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With Chronic Obstructive Pulmonary Disease(COPD)

Chronic Obstructive Pulmonary Disease

Germany
Novartis Pharmaceuticals

Completed

Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Maleate Via Concept1 or Simoon Devices

Asthma

Germany, Netherlands, United Kingdom
Novartis Pharmaceuticals

Completed

Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of Exacerbations

Chronic Obstructive Pulmonary Disease

Hong Kong
Novartis Pharmaceuticals

Completed

A Long-term Safety Study of QMF149 in Japanese Participants With Asthma

Asthma

Japan
Novartis Pharmaceuticals

Completed

Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma

Asthma

Germany, Belgium, India, Romania, South Africa, Croatia, Estonia, Russian Federation, Netherlands, Israel, Thailand, Lebanon, Canada, Philippines, Poland, Slovakia, United Kingdom, China, Latvia, Italy, Argentina, Greece, Mexico, Austria and more
Novartis Pharmaceuticals

Completed

Dose Ranging Study for Indacaterol in Japanese Asthma Patients

Asthma

Japan
Novartis Pharmaceuticals

Completed

Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.

Asthma

United States
Novartis Pharmaceuticals

Completed

Cardiac Safety of Indacaterol

Chronic Obstructive Pulmonary Disease | Healthy Volunteers

United States
BerGenBio ASA

Completed

A First-time-in-human Study of BGB149

Healthy Volunteers

United Kingdom
Novartis Pharmaceuticals

Completed

Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

COPD

United States
Novartis

Completed

Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States, Argentina, Germany, Spain, Canada, India, Turkey, Sweden, Italy
Centro Cardiologico Monzino
Novartis

Completed

Indacaterol in Heart Failure Patients: Any Role on Lung Fluid Regulation

Heart Failure

Italy
Novartis Pharmaceuticals

Completed

12-week Open-label Evaluation of Efficacy and Safety of Indacaterol (MOVE-ON)

Chronic Obstructive Pulmonary Disease (COPD)

Israel
Novartis Pharmaceuticals

Completed

Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients (FAVOR)

Chronic Obstructive Pulmonary Disease | COPD

Germany
BerGenBio ASA

Terminated

A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants

Ovarian Neoplasms

Korea, Republic of, Singapore, United Kingdom, Norway

3

Subscribe